Allogene Therapeutics SVP and CTO Benjamin Machinas Beneski Reports Disposal of Common Shares
Benjamin Machinas Beneski, SVP and CTO of Allogene Therapeutics Inc., reported the disposal of common shares of the company. This information was published via EDGAR by the U.S. SEC on November 19, 2025. The news is generated by Public Technologies using AI and is for informational purposes only.
Benjamin Machinas Beneski, SVP and Chief Technical Officer of Allogene Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allogene Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001737287-25-000094), on November 19, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
